[1] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[2] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[3] |
FU Xiaoyu, KONG Deguang, LI Juanjuan.
Treatment progress of triple positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
|
[4] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[5] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[6] |
CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing.
Clinical application and research progress of antibody drugs conjugation in breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
|
[7] |
LI Mengxi, ZHANG Kejing, XIA Fan.
Research progress in vaccine for breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
|
[8] |
WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying.
3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
|
[9] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
[10] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
[11] |
WU Shuai, YANG Jun, ZHENG Yun.
Dual role of miRNA in breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
|
[12] |
SHI Jingbin, XIONG Yang.
Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
|
[13] |
DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli.
Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
|
[14] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
[15] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|